Regeneron Pharmaceuticals Overview
Regeneron Pharmaceuticals Target Price
Analysts' 12-month price predictions for REGN.
Share Price
$903.48
Average Target Price
$1103.20
22.1% upside
22.1% upside5 analysts in the last 4 months
High: $1189 | Low: $1060
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2024-04-12 | JefferiesAkash Tewari | $1,060 | 17.3% upside |  |
| 2024-04-11 | RBC CapitalBrian Abrahams | $1,189 | 31.6% upside | |
| 2024-03-13 | Morgan StanleyMatthew Harrison | $1,115 | 23.4% upside | |
| 2024-01-12 | BMO CapitalBrian Abrahams | $1,076 | 19.1% upside | |
| 2024-01-12 | RBC CapitalBrian Abrahams | $1,076 | 19.1% upside | |
| 2023-03-27 | Leerink PartnersAndrew Berens | $976 | 8% upside | |
| 2023-03-24 | JefferiesAkash Tewari | $925 | 2.4% upside | |
| 2023-02-08 | EF Hutton | $853 |  5.6% downside | |
| 2023-02-06 | RBC Capital | $787 | 12.9% downside | |
| 2023-02-06 | Morgan Stanley | $883 | 2.3% downside | |
| 2023-02-06 | Leerink Partners | $834 | 7.7% downside | |
| 2022-11-11 | Guggenheim | $915 | 1.3% upside | |
| 2022-10-03 | Goldman Sachs | $970 | 7.4% upside | |
| 2022-09-16 | Canaccord Genuity | $750 | 17% downside | |
| 2022-09-13 | Piper Sandler | $775 | 14.2% downside | |
| 2022-09-12 | Wells Fargo | $800 | 11.5% downside | |
| 2022-09-09 | Barclays | $815 | 9.8% downside | |
| 2022-09-09 | Morgan StanleyMatthew Harrison | $851 | 5.8% downside | |
| 2022-09-08 | JefferiesAkash Tewari | $675 | 25.3% downside | |
| 2022-08-15 | Morgan StanleyMatthew Harrison | $625 | 30.8% downside | |
| 2022-08-04 | BMO Capital | $788 | 12.8% downside | |
| 2022-07-15 | Morgan Stanley | $619 | 31.5% downside | |
| 2022-06-29 | RBC CapitalKennen MacKay | $638 | 29.4% downside | |
| 2022-06-11 | Wells FargoMohit Bansal | $735 | 18.6% downside | |
| 2022-06-03 | Morgan Stanley | $610 | 32.5% downside | |
| 2022-05-31 | Argus Research | $760 | 15.9% downside | |
| 2022-05-23 | Leerink PartnersGeoffrey Porges | $738 | 18.3% downside | |
| 2022-05-23 | Credit SuisseLorenzo Biasio | $725 | 19.8% downside | |
| 2022-05-05 | Morgan Stanley | $620 | 31.4% downside | |
| 2022-04-16 | BarclaysCarter Gould | $745 | 17.5% downside | |
| 2022-02-13 | BMO CapitalEvan David Seigerman | $780 | 13.7% downside | |
| 2022-02-07 | BarclaysCarter Gould | $700 | 22.5% downside | |
| 2022-02-04 | J.P. MorganCory Kasimov | $604 | 33.1% downside | |
| 2022-02-04 | Cowen & Co.Tyler Van Buren | $640 | 29.2% downside | |
| 2022-02-04 | RBC CapitalKennen MacKay | $679 | 24.8% downside | |
| 2022-02-02 | Evercore ISIJoshua Schimmer | $680 | 24.7% downside | |
| 2022-01-18 | Morgan StanleyMatthew Harrison | $585 | 35.3% downside | |
| 2022-01-03 | BernsteinAaron Gal | $660 | 26.9% downside | |
| 2021-12-06 | Goldman SachsSalveen Richter | $824 | 8.8% downside | |
| 2021-11-10 | Cantor FitzgeraldAlethia Young | $760 | 15.9% downside | |
| 2021-09-09 | UBSEsther Rajavelu | $763 | 15.5% downside | |
| 2021-06-14 | Argus ResearchJasper Hellweg | $590 | 34.7% downside | |
| 2021-05-21 | Canaccord GenuityJohn Newman | $700 | 22.5% downside | |